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ABSTRACT
Plasmacytoid dendritic cells (pDCs) are key components of the innate immune response that are capable of synthesizing and
rapidly releasing vast amounts of type I interferons (IFNs), particularly IFN-. Here we investigated whether pDCs, often re-
garded as a mere source of IFN, discriminate between various functionally discrete stimuli and to what extent this reflects differ-
ences in pDC responses other than IFN- release. To examine the ability of pDCs to differentially respond to various doses of
intact and infectious HIV, hepatitis C virus, and H1N1 influenza virus, whole-genome gene expression analysis, enzyme-linked
immunosorbent assays, and flow cytometry were used to investigate pDC responses at the transcriptional, protein, and cellular
levels. Our data demonstrate that pDCs respond differentially to various viral stimuli with significant changes in gene expres-
sion, including those involved in pDC activation, migration, viral endocytosis, survival, or apoptosis. In some cases, the expres-
sion of these genes was induced even at levels comparable to that of IFN-. Interestingly, we also found that depending on the
viral entity and the viral titer used for stimulation, induction of IFN- gene expression and the actual release of IFN- are not
necessarily temporally coordinated. In addition, our data suggest that high-titer influenza A (H1N1) virus infection can stimu-
late rapid pDC apoptosis.
IMPORTANCE
Plasmacytoid dendritic cells (pDCs) are key players in the viral immune response. With the host response to viral infection being
dependent on specific virus characteristics, a thorough examination and comparison of pDC responses to various viruses at vari-
ous titers is beneficial for the field of virology. Our study illustrates that pDC infection with influenza virus, HIV, or hepatitis C
virus results in a unique and differential response to each virus. These results have implications for future virology research, vac-
cine development, and virology as a whole.
Innate immunity provides a first line of defense for eukaryoticorganisms to evade viruses and other pathogens (1). This first
line of defense is activated in response to the detection of patho-
gen-associated molecular patterns (PAMPs) by cellular pattern
recognition receptors (PRRs) (2). Once foreign PAMPs are de-
tected, intracellular signaling pathways are activated that result in
the initiation of numerous defense mechanisms, including the
production of protective cytokines (3). Immune activation
through cytokine secretion and subsequent recruitment of im-
mune effector cells of the cellular innate and adaptive immune
systems to the site of infection complete the host immune re-
sponse (4).
Of particular importance are interferons (IFNs), a cytokine
family of proteins involved in the activation of immune cells, up-
regulation of antigen presentation, and signaling of uninfected
host cells to resist infection (5). The IFN family of cytokines is
composed of type I IFNs (IFN-, IFN-, and IFN-), a type II IFN
(IFN-), and a type III IFN (IFN-) (6). Following secretion from
infected cells, IFNs can act in an autocrine or paracrinemanner by
binding to specific cell surface receptors to initiate the induction
of a growing number of IFN-stimulated genes (150) via signal-
ing through the Janus protein kinase (JAK)/signal transducer and
activator of transcription (STAT) pathway (7).
Dendritic cells are critical components of innate and adaptive
immunity that can detect foreign antigens and present them to
other effector cells of the immune system (8). Furthermore, a
subset of these cells, plasmacytoid dendritic cells (pDCs), can pro-
duce copious amounts of IFN- and other cytokines in response
to foreign molecules to further bolster the immune response (9).
As a result of this ability, pDCs play a central role in antiviral
immunity (10). Though the response of pDCs can vary, depend-
ing on the type and magnitude of viral infection, the significance
of activated pDCs for early type I IFN production is undisputed
(11, 12).
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Of particular importance is the role of pDCs during influenza
virus infection, amajor problem globally with a significant impact
on vulnerable populations, including the young, elderly, and im-
munocompromised. pDCs mitigate influenza virus infection
through the early secretion of type I IFN and subsequent antigen
presentation (13). Though pDCs have been shown to be dispens-
able in mice during sublethal influenza virus infection, their role
during lethal infection has yet to be investigated (14).
In this study, we investigated the in vitro antiviral responses of
human pDCs to various doses of influenza virus by not only con-
sidering IFN- production but also compiling data on gene ex-
pression and protein production following infection. Other RNA
viruses, namely, human immunodeficiency virus (HIV) and hep-
atitis C virus (HCV), were also included in this study for compar-
ison and to point out potential analogies and/or differences be-
tween pDC antiviral responses. Distinct antiviral responses were
observed among the pathogens. Moreover, we observed a dose-de-
pendent response inpDCs specifically to the influenza virus,withour
data suggesting that while low-titer infection with H1N1 influenza
virus triggers robust productionof type I IFN, high-titerH1N1 influ-
enza virus infection can stimulate rapid pDC apoptosis.
MATERIALS AND METHODS
Blood samples, processing, viral stimulation, and ELISA.Whole blood
collected for this study was obtained from healthy donors by the Depart-
ment of Transfusion Medicine, Clinical Center, National Institutes of
Health, over 2 years under an Institutional Review Board-approved re-
search protocol. Buffy coats were subjected to Ficoll-based density
gradient centrifugation to obtain peripheral blood mononuclear cells
(PBMCs). Samples were enriched for pDCs via magnetic-bead-associated
cell sorting with the Miltenyi Biotec (Auburn, CA) human pDC isolation
kit for negative selection. pDC purity was ascertained by labeling for
BDCA-4, and the samples used were, on average, 92% pure. The total
amount of pDCs isolated was used to maximize the total RNA yield for
microarray analysis. From 8 104 to 2.5 105 pDCswere cultured for 18
h in 1 ml of AIM V serum-free medium CTS (Life Technologies, Grand
Island, NY) and interleukin-3 (IL-3) by Symansis (Auckland, New Zea-
land) at 10 ng/ml. After 18 h in culture, pDCs were stimulated with virus
for 6 h before RNA isolation or analysis by flow cytometry. Cell culture
supernatant was collected after 6 h of viral stimulation and stored at
	20°C. An enzyme-linked immunosorbent assay (ELISA) for IFN- and
IFN- was performed with kits purchased from PBL Interferon Source
(Piscataway, NJ). An ELISA for IL-28 was done with kits purchased from
R&D Systems (Minneapolis, MN).
Gene expression arrays. Total RNA was isolated from virus-stimu-
lated samples and untreated controls with Qiagen RNeasy Plus microkits
(Qiagen, Valencia, CA) and used for two-color gene expression array
experiments. Samples were amplified into antisense RNA (aRNA) by a
two-cycle amplification procedure with the MessageAmp II aRNA kit
(Ambion, Grand Island, NY) and compared indirectly with a pool of total
RNA derived from independent human PBMCs serving as a common
reference. Both reference and test aRNA samples were directly labeled
with the Kreatech (Durham, NC) ULS aRNA fluorescent labeling kit with
Cy3 for reference samples and Cy5 for test samples. Whole-genome hu-
man 36K oligonucleotide arrays representing 25,100 unique genes of the
Operon Human Genome Array-Ready Oligo Set, version 4.0, were
printed in house with oligonucleotides purchased from Operon. The de-
sign is based on the Ensembl Human Database build NCBI-35c, with full
coverage on the NCBI human RefSeq data set (04/04/2005). Hybridiza-
tion was carried out in a water bath at
42°C for 18 h, and the arrays were
then washed and scanned on a microarray scanner (Agilent, Santa Clara,
CA). Human array transcriptional data were uploaded to the mAdb data
bank (http://nciarray.nci.nih.gov) and analyzed with BRBArrayTools de-
veloped by the Biometric Research Branch, National Cancer Institute
(http://linus.nci.nih.gov/BRB-ArrayTools.html) (15) or PartekGenomics
Suite software (Partek, St. Louis, MO), as appropriate. Raw data sets were
normalized by using the median over the entire array or the robust mul-
tiarray average. Absent background values were handled by the k–nearest-
neighbor imputation approach at a k value of 15 as described previously
(16). Experimental-array batches were merged into a single set of mi-
croarrays by distance-weighted discrimination as described elsewhere
(17). Analysis of variance (ANOVA) was used to identify genes that were
differentially expressed between samples infected with different viruses
and their respective controls. Differences were visualized by hierarchical
clustering of the genes retrieved from the ANOVA. Functional gene net-
work analysis was performed by Ingenuity pathway analysis (Ingenuity
Systems).
Flow cytometry. Stimulated pDCs were washed twice with 1 phos-
phate-buffered saline (PBS; Gibco) and then incubatedwithMiltenyi Bio-
tec (Auburn, CA) FcR Blocking Reagent for 20 min at 4°C. pDCs were
then triple stained for annexin V from eBioscience (San Diego, CA),
7-amino-actinomycin D (7AAD) from BD (Franklin Lakes, NJ), and
BDCA-4 from R&D Systems (Minneapolis, MN) and incubated for 30
min at 4°C. Cells were then washed once more with Miltenyi Biotec Au-
toMACS running buffer and then analyzed on a BD FACSCalibur flow
cytometer.Datawere evaluated by the FlowJo software. Appropriate com-
pensation settings for signal spillover control were determined with BD
Calibrite beads. Specific fluorescence signals were calculated by normal-
ization to the appropriate isotype controls.
Viruses. Direct pelleted HIV-1 IIIB and BaL were purchased from
Advanced Biotechnologies Inc. (Columbia, MD). Influenza A/PR/8/34
(H1N1) purified virus was purchased from Charles River Laboratories
International Inc. (Wilmington, MA), Advanced Biotechnologies (Co-
lumbia,MD), and the American TypeCulture Collection (ATCC;Manas-
sas, VA). HCV JFH-1 was provided by T. Jake Liang, Liver Diseases
Branch, National Institute of Diabetes and Digestive Diseases, NIH.
PB1-F2 knockout (KO) and rescue influenza A/PR/8/34/Mount Sinai
(H1N1) viruses were provided by Jonathan W. Yewdell, Laboratory of
Viral Diseases, National Institute of Allergy and Infectious Diseases, NIH.
Hemagglutination inhibition titers of PB1-F2 KO and rescue viruses were
determined with Turkey erythrocytes (Lampire Biological Laboratories)
diluted to 1% in 1 PBS for 1 h.
Image stream.Cell vitality was assayed with the ImageStreamX imag-
ing flow cytometer (Amnis, Seattle, WA) equipped with 405-, 488-, and
642-nm laser excitation (ex) light sources; a 12-channel, dual-camera flu-
orescence detection system sensitive to fluorophore emission (em) in the
violet-to-near-infrared light spectrum; and a 60 0.9 numerical aperture
objective. Cells were stained with the non-membrane-permeating DNA
dye Hoechst 33342 (ex, 405 nm; em, 430 to 505 nm) and the non-mem-
brane-permeating DNA dye propidium iodide (PI) (ex, 488 nm; em, 592
to 642 nm) and imaged at a flow rate of500 cells/s, with a total of 10,000
cells acquired for each sample. Cell imagery was processed with IDEAS
image analysis software (Amnis). All nucleated cells were labeled with
Hoechst 33342. Live cells were identified as PI negative, whereas dead cells
were colabeled with both Hoechst 33342 and PI.
Microarray data accession number.Data from the 95microarray ex-
periments have been uploaded to the GEO database with accession num-
ber GSE59837.
RESULTS
In order to investigate the responses of human pDCs obtained
from healthy blood donors to distinct human RNA viruses, pDCs
were isolated by negative selection from PBMCs and cultured for
18 h prior to infection as previously described (18). Using this
method, we were able to obtain a 92% pure pDC population for
our experiments (see Fig. S1 in the supplemental material). With
influenza virus-stimulated pDCs shown to produce IFN- as early
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as 3 h (19), we chose to investigate a relatively early stage of pDC
activation by using the 6-h time point for comparison.
Initially, we sought to characterize the pDC in vitro responses
to various doses of H1N1 influenza virus, HIV, and HCV. Four
doses each of H1N1 influenza virus and HIV and three doses of
HCVwere used to investigate pDC responses. The doses usedwere
chosen to cover the range of viral titers typically reported in re-
spective viral infections or doses proven to stimulate pDCs in vitro
(13, 19).We treated pDCs from three individual donors with each
virus before lysing the cells for RNA isolation and collecting the
cell culture supernatant to examine both IFN-mRNA levels and
protein production via microarray analysis and ELISA, respec-
tively (Fig. 1). Distinct responses were observed for each virus at
both the mRNA and protein levels.
When examining IFN-mRNA levels following pDC stimula-
tionwith various doses ofH1N1 influenza virus,maximumIFN-
gene expression was observed at the lowest titer used (4 hemag-
glutination units [HAU]/ml). Interestingly, a gradual decrease in
IFN- gene expression was detected as the dose was increased. At
the highest titer of 2,048 HAU/ml, we observed minimal changes
in IFN- gene expression above the baseline (Fig. 1A) and this
corresponded to a broader dampening of the expression of IFN-
stimulated genes. In experiments performedwith increasing doses
of HIV, we observed a corresponding increase in IFN- gene ex-
pression (Fig. 1B). In striking contrast, we observed minimal
changes in gene expression regardless of the dose of HCV used
(Fig. 1C).
We next sought to compare the changes observed in IFN-
mRNA levels with those observed at the protein level as deter-
mined through ELISA. Following stimulation of pDCswithH1N1
influenza virus, we detected the production of large amounts of
IFN- in the supernatant compared to those in the uninfected
controls. Regardless of the dose used, large amounts of IFN-
protein were secreted into the cell culture supernatant (Fig. 1D).
When we examined IFN- protein production following pDC
stimulation with HIV, we observed a dose-dependent increase in
cytokine production in all three donors tested that mirrored the
IFN- mRNA levels (Fig. 1E); however, at the doses used, H1N1
influenza virus appeared to be a more potent stimulus, with ap-
proximately 10 times as much IFN- protein being produced.
Similar to what was observed at the mRNA level, we were unable
to detect the production of IFN-protein above the baseline levels
following stimulation with HCV (Fig. 1F). The results were simi-
lar, as expected, whenwe corrected for the number of cells present
in each experiment (see Fig. S2 in the supplemental material).
To corroborate these findings, we performed additional exper-
iments with pDCs from10 separate donors and directly compared
the type I and III IFN protein levels produced following stimula-
FIG 1 Differential regulation of IFN- in pDCs exposed to H1N1 influenza virus, HIV, and HCV JFH-1. pDCs from three separate donors were exposed to
various concentrations of virus. (A) Heat maps generated with microarray data of the IFN- genes from pDCs stimulated with PBS (control) or influenza virus
A/PR/8/34 (H1N1; Charles River Laboratories) at 4, 32, 256, or 2,048 HAU/ml. (B) Heat maps generated with microarray data of the IFN- genes from pDCs
stimulated with PBS (control) or HIV-1 IIIB (Advanced Biotechnologies) at 1.00102, 1.00103, 1.00 104, or 1.00105 50% tissue culture infective doses
(TCID50)/ml. (C) Heat maps generated with microarray data of the IFN- genes from pDCs stimulated with PBS (control 1), conditioned medium (control 2),
orHCVat 1.00104, 1.00105, or 1.00 106 RNA copies/ml. (D)Quantification of IFN- protein production by ELISA in pDCs stimulatedwith PBS (control)
or influenza virus A/PR/8/34 (H1N1; Charles River Laboratories) at 4, 32, 256, or 2,048 HAU/ml. (E) Quantification of IFN- protein production by ELISA in
pDCs stimulatedwith PBS (control) orHIV-1 IIIB (Advanced Biotechnologies) at 1.00102, 1.00103, 1.00 104, or 1.00105 TCID50/ml. (F)Quantification
of IFN- protein production by ELISA in pDCs stimulated with PBS (control 1), conditioned medium (control 2), or HCV at 1.00104, 1.00105, or 1.00
106 RNA copies/ml. *,P 0.05; **,P 0.01 (determined by ratio paired t test comparedwith the corresponding control). NS, not significant. ND, not detectable.
Thomas et al.
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tion with the three distinct viruses at the dose that resulted in
maximal IFN- induction at both the mRNA and protein levels.
In addition, a second strain of HIVwas included in this analysis to
confirm the differences observed between H1N1 influenza virus
and HIV and also account for potential differences between R5
and X4 HIV strains in this regard. Figure 2A clearly shows that
H1N1 influenza virus is the most potent of these viruses in stim-
ulating IFN- protein production, with lower levels produced by
the two distinct strains of HIV and no IFN- release observed
upon pDC exposure to HCV. Similarly, Fig. 2B shows that H1N1
influenza virus is the most potent of these viruses in stimulating
IFN- protein production, with lower levels produced by the two
distinct strains of HIV and no IFN- release observed upon pDC
exposure to HCV. Interestingly, we observed minimal protein
production of the type III IFN IL-28 following stimulation by all of
the viruses (Fig. 2C).
Since we observed strong activation of the antiviral response
following stimulation with H1N1 influenza virus and HIV, we
next further characterized the changes in global gene expression in
pDCs following stimulation with these viruses at titers that elicit
maximum IFN- stimulation. Figure S3 in the supplemental ma-
terial shows that although these viruses stimulate the upregulation
and production of type I IFNs (Fig. 1 and 2), they elicit distinct
changes in global gene expression. Specifically, when H1N1 influ-
enza virus and HIV-1 IIIB were compared, H1N1 influenza virus
inducedprimarily IFNs and ILswhereasHIV-1 IIIB induced genes
related to antigen presentation and regulation of transcription
(see Fig. S3A and Table S1A in the supplemental material). When
HIV-1 IIIB-induced changes were compared to those found fol-
lowing stimulation with HIV-1 BaL, there were very similar
changes in the transcriptome; however, of the few genes that were
differentially regulated, it appeared that HIV-1 IIIB elicited a
more potent immune response in pDCs (see Fig. S3B and Table
S1B). This result mirrors data from Fig. 2A and B, where HIV-1
IIIB triggered greater IFNproduction thanHIV-1BaL. Figure S3C
and Table S1C further demonstrate that HIV-1 BaL was the
weaker immune stimulator of the two HIV strains examined.
Analysis of the transcriptome followingHCV stimulation of pDCs
demonstrated minimal differences from the untreated controls
(data not shown).
To further characterize the difference in the changes in the
transcriptome following stimulation with these viruses, we deter-
mined the number of differentially expressed genes. Using
ANOVA (change, 1.5-fold; P 0.05), we found 717, 503, and 177
genes to be differentially expressed between uninfected controls
and H1N1 influenza virus-, HIV-1 IIIB-, and HIV-1 BaL-infected
pDCs, respectively. Subsequently, we used these gene lists to iden-
tify genes whose expression patterns overlap between the samples
stimulatedwith the distinct viruses. Overall, 155 genes were found
to be differentially expressed following infection with both H1N1
influenza virus and HIV (Fig. 3A). Ingenuity pathway analysis of
these 155 genes revealed an enrichment of the genes in various
biological processes. As expected, the antiviral IFN response was
themost upregulated pathway observed, withmany other affected
processes associated mainly with inflammation and ancillary viral
responses (Fig. 3B).
Since we observed that, specifically for H1N1 influenza virus,
there was a difference in the antiviral response involving IFN-
gene expression between the low titer of 4 HAU/ml and the high
titer of 2,048HAU/ml, we chose to perform an additional analysis
of the data set obtained by microarray analysis of these RNA sam-
ples. Figure 4 reports the most significant biological pathways af-
fected and the genes with the greatest changes in gene expression
that were specifically altered by low- or high-titer influenza virus
infection. The low titer of H1N1 influenza virus clearly elicited a
strong antiviral response characterized by the activation of innate
immune pathways, specifically, many known IFN-related gene
networks (Fig. 4A). Interestingly, the high titer of H1N1 influenza
virus stimulated a distinct change in the transcriptome with the
absence of induction of the IFN- family members (Fig. 1D). To
explore why IFN- gene induction was absent when the high titer
of H1N1 influenza virus was used, Ingenuity pathway analysis of
differentially expressed genes showed gene expression patterns re-
lated to apoptosis signaling and mitochondrial dysfunction that
can subsequently lead to cell death (Fig. 4B).
To further investigate the effect of high-titer influenza virus
infection and the possible induction of apoptosis in pDCs, flow
cytometry was used in conjunction with cell death markers to
investigate this observation. In order to also rule out a contami-
nation effect due tomanufacturing, we usedH1N1 influenza virus
isolates from three different sources (Fig. 5). All three viruses
stimulated the production of similar amounts of IFN- protein by
infected pDCs, and the levels of these protein from pDCs isolated
from three separate donors were consistently high (Fig. 5A). In-
FIG 2 Differential protein production of type I and III IFNs in pDCs treated withH1N1 influenza virus, HIV-1 IIIB, HIV-1 BaL, orHCV. ELISA of supernatants
from pDCs from 10 separate donors treated with PBS (control), HCV at 1.00 106 RNA copies/ml, HIV-1 BaL 1.00105 TCID50/ml (Advanced Biotechnol-
ogies), HIV-1 IIIB at 1.00105 TCID50/ml (Advanced Biotechnologies), or influenza virus A/PR/8/34 (H1N1; Charles River Laboratories) at 4 HAU/ml. (A)
IFN- protein. (B) IFN- protein. (C) IL-28 protein. *, P 0.05; **, P 0.01; ***, P 0.005 (determined by ratio paired t test comparedwith the corresponding
control). NS, not significant.
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terestingly, we observed an enlarged population of pDCs follow-
ing influenza virus treatment that was not present in untreated
samples (Fig. 5B and C). In the influenza virus-treated samples,
three distinct populations based on size were present and were
designated populations I (cell debris/apoptotic remnants), II, and
III (Fig. 5C). Following gating of the samples, we labeled them
with the pDC marker BDCA-4 and with the corresponding cell
death markers annexin V and 7AAD to distinguish between early
and late apoptosis, respectively. Compared with untreated con-
trols, the cells in gate III demonstrated greater staining for early
apoptosis markers than those in gate II (Fig. 5D). Similarly, com-
pared to untreated controls, the cells in gate III demonstrated
greater staining for late apoptosis than those in gate II (Fig. 5E).
Since this experiment was performed with the highest titer of
H1N1 influenza virus, we also investigated the effect of the lowest
titer of H1N1 influenza virus used on pDC cell size. Figure 6 dem-
onstrates that although there were similar effects on cell size fol-
lowing treatment with both the high and low titers of H1N1 influ-
enza virus, it was only the high titer that resulted in marked
induction of apoptosis. This observation was confirmed through
the significant increase in cell debris and apoptotic remnants in
population I and the decrease in viable cells in population II (Fig.
6B), further confirming the data provided in Fig. 4. To further
characterize populations I, II, and III and to validate 7AAD stain-
ing, imaging flow cytometry of stimulated pDCs stained with
Hoechst 33342 and PI was performed. Figure 6C and D demon-
strate that the greater cell death in population III than in popula-
tion II following treatment with either a high or a low titer is
associated with the enlargement of individual dying cells, thus
excluding the possibility that the larger size was due to the forma-
tion of cell agglomerates. In addition, PI staining confirmed that
the cells in gate I were dead cells and debris.
To further investigate the mechanism of influenza virus-in-
duced pDC apoptosis, we also used mutant H1N1 influenza virus
strains. Specifically, PB1-F2 KO and rescue H1N1 influenza virus
strains were used to determine if the PB1-F2 viral protein, previ-
ously found to disrupt mitochondrial function in influenza virus-
infected HeLa cells, contributes to the induction of apoptosis in
infected pDCs (20). Following stimulation, the levels of IFN-
protein produced were consistently high among all of the H1N1
influenza virus-treated samples, including the mutant and rescue
strains determined by ELISA (see Fig. S4A in the supplemental
material). In addition, compared with untreated controls, as ob-
served previously, the cells in population III had greater levels of
early apoptosis markers in all H1N1 influenza virus-treated sam-
ples, including the mutant and rescue strain, than standard-size
FIG 3 Changes in gene expression and biologic pathways affected following infection with H1N1 influenza virus andHIV. pDCs were stimulated with influenza
virus A/PR/8/34 (H1N1; Charles River Laboratories) at 4 HAU/ml, HIV-1 IIIB (Advanced Biotechnologies) at 1.00105 TCID50/ml, or HIV-1 BaL (Advanced
Biotechnologies) at 1.00105 TCID50/ml. (A) Venn diagram displaying the numbers of differentially expressed genes in control versus virus-stimulated pDCs.
The value next to each virus name is the total number of differentially expressed genes versus the uninfected control. (B) Top canonical biological pathways
associated with the overlapping 155 differentially expressed genes in virus-stimulated samples. The stacked bar chart displays for each canonical pathway the
number of genes found to be significantly upregulated (red) or downregulated (green) by Bayesian model selection. The molecules or genes in a given pathway
that were not found on our list of significantly regulated genes are termed not overlapping with our data set (white). The value at the top of each bar represents
the total number of genes or molecules in the canonical pathway. The Benjamini-Hochberg (B-H) method was used to adjust the right-tailed Fisher exact t test
P values, which measure how significant each pathway is.
Thomas et al.
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(population II) pDCs (see Fig. S4B and C). Similarly, the number
of cells undergoing late apoptosis because of both the PB1-F2 KO
and rescue strains mirrored that of the low- and high-titer wild-
type influenza virus-treated samples (see Fig. S4C), indicating that
the PB1-F2 protein caused minimally increased apoptosis in
pDCs.
DISCUSSION
pDCs are critically important for the initiation and propagation of
a successful immune response to viral pathogens (21). One of the
mechanisms by which they accomplish this is the robust produc-
tion of type I IFNs following the detection of viral PAMPs (9).
Here, we compared the responses of pDCs to three distinct viral
pathogens in order to characterize themanner in which these cells
attempt to control these diverse pathogens. Two of these RNA
viruses (HIV and HCV) can cause chronic infections, while influ-
enza virus causes an acute infection that is subsequently cleared by
the human immune system in most instances (22).
We initiated the study examining the production of the type I
IFN, namely, IFN-. Interestingly, we observed distinct responses
in pDCs following stimulation with the viruses tested. As ex-
pected, both influenza A virus and HIV stimulated a robust anti-
viral response in the pDCs that was characterized by massive up-
regulation of IFN- mRNA and subsequent protein production
(Fig. 1) (19). Interestingly, there were significant differences be-
tween these antiviral responses. In the case of HIV, the antiviral
response became stronger as the infective dose of HIV used to
stimulate the pDCs was increased at both the mRNA and protein
levels (Fig. 1B and E). Surprisingly, following exposure of pDCs to
influenza virus, we observed the highest production of type I IFN
mRNA at the lowest titer used in this study (Fig. 1A). Further-
more, the amount of IFN- produced when a higher titer of in-
fluenza virus was used did not increase significantly, as was ob-
served with HIV (Fig. 1D and E). To confirm the effect of HIV on
pDC IFN production, we used two different strains of HIV. In
addition, the second strain of HIV was included to account for
potential differences betweenHIV strains R5 andX4.When found
in HIV-infected patients, X4-trophic viruses (HIV-1 IIIB) can
lead to accelerated disease progression with a rapid decline of
CD4
 andCD8
T cells compared to that in patients infectedwith
R5 strains (HIV-1 BaL) (23, 24). Our data showing increased up-
regulation of several immune-related genes in HIV-1 IIIB-in-
fected versus HIV-1 BaL-infected pDCs (see Fig. S3b in the sup-
plemental material) may provide insight into these clinical
findings; however, further studies are needed to clarify this.
In contrast, of the three viruses, minimal production of IFN
was seen in pDCs exposed to high titers of the HCV virus. HCV is
known to infect hepatocytes exclusively (25); however; it was pre-
dicted that pDCs, with their robust expression of a diverse array or
PRRs, would be able to detect distinct components of this virus
regardless of whether the cells were directly infected with the sub-
sequent product of replication intermediates. Surprisingly, mini-
mal stimulation was observed following global transcriptome
analysis in these cells exposed to HCV (Fig. 1C). On the basis of
these data, one can speculate that the HCV virion has potent
mechanisms to suppress the activation of pDC innate immune
responses that canusuallydetectmostotherpathogens.Alternatively,
FIG 4 Microarray analysis of pDCs infected with H1N1 influenza virus. Gene lists are based on two-way ANOVAs comparing low-titer H1N1 influenza virus
with the control (A) and high-titer H1N1 influenza virus with the control (B). Change, 1.5-fold (P 0.01).
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pDCsmay simply be incapable of detectingHCV-associated PAMPs
unless the contact is mediated through other intermediary mecha-
nisms (26). Stone et al. have recently demonstrated that components
of theHCVgenomecanstimulate IFNproduction inpDCs(27).This
publication is significant because an indirect transfer of viral genetic
material may be occurring in vivo between pDCs and HCV-infected
hepatocytes that may trigger IFN production from pDCs.
When mRNA levels of the IFN- family were specifically ex-
amined, there was a decrease in mRNA upregulation when the
highest titers of influenza virus were used (Fig. 1A). To explore
this further, we used Ingenuity pathway analysis of themicroarray
data, which subsequently demonstrated that pDCs infected with
high titers of influenza virus may undergo programmed cell death
(Fig. 4B). In order to confirm this, we used flow cytometry and
three different isolates of H1N1 influenza virus and saw that, in-
deed, exposure of pDCs to a high virus titer results in cell death
(Fig. 5). To characterize the mechanism by which influenza A
virus is able to do this, we used mutant influenza viruses lacking
viral components that are known to trigger cell death (20) and we
were unable to observe that the PB1-F2 viral protein is important
for triggering cell death in pDCs (see Fig. S4 in the supplemental
material).However, it was demonstrated that an influenza vaccine
can also cause cell death in pDCs, further demonstrating the abil-
ity of viral components to trigger this phenomenon (data not
shown).
The triggering of influenza virus-activated pDC cell death is
biologically relevant since it has been demonstrated that individ-
uals who succumb to influenza virus infection do so following the
triggering of a virus-induced cytokine storm (28). This influenza
virus-induced apoptotic pDC death may be one mechanism by
which the immune system attempts to minimize the overproduc-
tion of antiviral and inflammatory cytokines following infection.
FIG 5 Increased apoptosis in pDCs infected with a high titer of H1N1 influenza virus. pDCs from three separate donors were stimulated with PBS (control),
influenza virus A/PR/8/34 (H1N1-1; Charles River Laboratories) at 2,048 HAU/ml, influenza virus A/PR/8/34 (H1N1-2; Advanced Biotechnologies) at 2,048
HAU/ml, or influenza virus A/PR/8/34 (H1N1-3; ATCC) at 105.2 50% chicken embryo infective doses/ml. (A) Quantitation of IFN- protein by ELISA of
supernatants from pDCs following infection with H1N1-1, H1N1-2, and H1N1-3 influenza viruses. Representative flow cytometry side scatter versus forward
scatter plot of untreated pDCs (B) and H1N1 influenza virus-treated pDCs (C). (D) Flow cytometry plots of BDCA- and annexin V-stained pDCs treated with
PBS or H1N1-1, H1N1-2, or H1N1-3 influenza virus. (e) Flow cytometry plots of BDCA-4 and 7AAD double-stained pDCs treated with PBS or H1N1-1,
H1N1-2, or H1N1-3 influenza virus. ***, P 0.005 (determined by ratio paired t test compared with the corresponding control). ND, not detectable.
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In addition, a recently published study (29) demonstrated that
type I IFN itself can result in decreased numbers of pDCs in mice.
Therefore, we propose that pDCs, after the initial detection of a
large amount of a viral pathogen and subsequent type I IFN secre-
tion, negatively regulate their own numbers to ensure that only
limited amounts of IFNare generated. Thismay be facilitated both
through IFN signaling (30) and also by the more rapid activation
of a direct apoptotic program that causes cell enlargement as an
intermediary state toward the removal of the pDCs that are in-
fected with a large quantity of virus. We hypothesize that in most
individuals, this pathway is sufficient to minimize cytokine re-
sponses in instances where a large pathogen inoculum is encoun-
tered; however, in some individuals, a cytokine storm is produced
from cells of the innate immune system that results in the death of
the host (28). In addition, airway epithelium cell death has also
been reported to occur during influenza virus infection. This vi-
rus-triggered cell death is thought to serve multiple purposes in
host protection, including removal of the source of replicating
virus. The death of these cells infected with high titers of virus will,
in turn, both limit the further spread of the virus in the respiratory
tract and decrease the levels of potentially damaging proinflam-
matory cytokines (31). Further study of this phenomenon in
pDCs is warranted, as deficiencies in these and similar pathways to
limit an immune response may also result in autoimmunity and
perhaps other pathological states in humans.
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